EUVIMEDEUVIMED entdecken
Crossref

Optical control of butyrylcholinesterase (BChE) activity via photoswitchable azobenzene for potential treatment of Alzheimer’s disease

Lei Wang, Ziming Gao, Tianyu Sun, Chen Chen, Jiawei Zhu, Suyu Wang, Yao Chen, Haopeng Sun

Bioorganic Chemistry · 2024-12 · 153 · 107845

DOI: 10.1016/j.bioorg.2024.107845 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic Chemistry, 2024-12. Verfasst von Lei Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China. Hauptthemen laut MEDLINE: Butyrylcholinesterase, Azo Compounds, Alzheimer Disease, Cholinesterase Inhibitors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Photopharmacology is an emerging method in medicinal chemistry to achieve light-controlled drug activity. Azobenzene-based photoswitchable ligands have found widespread application as chemical tools in photopharmacological studies. This study pioneers the design and synthesis of a novel series of photoswitchabled butyrylcholinesterase (BChE) inhibitors, achieved by strategically integrating an azo moiety into an N-benzyl benzamide scaffold. Through a meticulous investigation of the structure-activity relationship (SAR), we discovered that the lead compound, Azo-9, exhibits dynamic cis/trans conformational shifts, dynamically modulating its BChE-binding efficacy. This unique property translates into potential therapeutic benefits, including neuroprotection and cognitive enhancement. Complementary molecular docking simulations underscored the preferential binding of the cis-isomer of Azo-9 to BChE, which was subsequently validated in a glutamate-mediated neuronal injury model. Collectively, Azo-9 emerges as a promising precision tool for Alzheimer's disease (AD) therapy, while also facilitating deeper insights into the disease's underlying mechanisms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ButyrylcholinesteraseAzo CompoundsAlzheimer DiseaseCholinesterase InhibitorsMolecular Docking SimulationStructure-Activity RelationshipHumansMolecular StructureNeuroprotective AgentsAnimalsDose-Response Relationship, DrugPhotochemical Processes

Substanzen

ButyrylcholinesteraseAzo CompoundsazobenzeneCholinesterase InhibitorsNeuroprotective Agents

Autor:innen und Institutionen

  • School of Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China.
  • School of Pharmacy, Nanjing Medical University, Nanjing 211166, PR China.
  • School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing 210023, PR China. Electronic address: 300630@njucm.edu.cn.
  • School of Pharmacy, China Pharmaceutical University, Nanjing 211198, PR China. Electronic address: sunhaopeng@cpu.edu.cn.

Zitieren

APA

Wang, L., Gao, Z., Sun, T., Chen, C., Zhu, J., Wang, S., Chen, Y., & Sun, H. (2024). Optical control of butyrylcholinesterase (BChE) activity via photoswitchable azobenzene for potential treatment of Alzheimer’s disease. Bioorganic Chemistry, 153, 107845. https://doi.org/10.1016/j.bioorg.2024.107845

Vancouver

Wang L, Gao Z, Sun T, Chen C, Zhu J, Wang S, et al. Optical control of butyrylcholinesterase (BChE) activity via photoswitchable azobenzene for potential treatment of Alzheimer’s disease. Bioorganic Chemistry. 2024;153:107845. doi:10.1016/j.bioorg.2024.107845

BibTeX
@article{Wang2024,
  author = {Wang, Lei and Gao, Ziming and Sun, Tianyu and Chen, Chen and Zhu, Jiawei and Wang, Suyu and Chen, Yao and Sun, Haopeng},
  title = {Optical control of butyrylcholinesterase (BChE) activity via photoswitchable azobenzene for potential treatment of Alzheimer’s disease},
  journal = {Bioorganic Chemistry},
  year = {2024},
  volume = {153},
  pages = {107845},
  doi = {10.1016/j.bioorg.2024.107845}
}
Kostenlos starten →